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Collision of Three Pandemics: The
Coexistence of Cervical Cancer, HIV
Infection, and Prior Tuberculosis in the
Sub-Saharan Country of Botswana
executive
sum
m
ary
Cervical cancer is the leading cause of cancer-related mortality in the developing world, where HIV and
Mycobacterium tuberculosis (TB) infection are also endemic. HIV infection is independently associated
with increased morbidity and mortality among women with cervical cancer. TB is believed to increase the
risk of malignancies and could cause chronic inflammation in the gynecologic tract. However, the re-
lationship between cervical cancer and TB in settings hyperendemic for HIV is unknown.We found that 18
(10%) of a cohort of 180womenwith cervical cancer in Botswana had a history of TB disease. Age andHIV
infection were also associated with a history of TB disease. Our data show that prior TB disease is highly
prevalent among patients with cervical cancer infected with HIV. The coexistence of cervical cancer, HIV
infection, and prior TB infection might be higher than expected in the general population. Prospective
studies are needed to better determine the impact of the collision of these three world health epidemics.
INTRODUCTION
Cervical cancer is the third most common malig-
nancy in women worldwide and the leading cause
of cancer-related death for women in developing
countries. Globally, it is estimated that approxi-
mately half a million women are diagnosed with
cervical cancer every year, and approximately
275,000 women die of the disease, 85% of whom
live in low- and middle-income countries.1 In Bot-
swana, cervical cancer is the most common gyne-
cologic cancer and the leading cause of cancer
death.2,3
HIV infection accelerates the progression toward
cervical cancer and likely is associated with worse
clinical outcomes.4 In Botswana, 60% of patients
diagnosed with cervical cancer are also infected
with HIV.2,5 With cervical cancer rates rising in
developing countries where HIV is endemic, iden-
tifying and understanding the factors leading to
increased morbidity and mortality in these popu-
lations should be a priority.6
The devastating impact of the colliding HIV and
tuberculosis (TB) pandemics in resource-limited
settings has been long recognized.7 HIV infection
is one of the most important risk factors for pro-
gression to active TB disease. Furthermore, TB is
the number one killer of people living with HIV in
the world.5 Importantly, the impact of these pan-
demics is more severe in countries with more
challenging health care systems, where TB and
HIV are less controlled, and patients may have
more advanced disease states compared with the
developedworld. Botswana has one of the highest
TB prevalence rates in the world, and it is esti-
mated that 60% to 75% of people diagnosed with
TB are coinfected with HIV.8
An association betweenmalignancies and TBwas
previously established.9 TB has been implicated
in the pathogenesis of malignancies and may
interfere with their diagnosis. TB and cancer fre-
quently coexist, and the relative immunosuppres-
sion caused by cancer or its treatmentmay lead to
reactivation of latent TB infections, leading to in-
creased morbidity and mortality.9 However, data
on the association between cervical cancer and
TB are scarce.10
Despite themagnitude of the cervical cancer, HIV,
and TB epidemics coexisting in many resource-
limited settings, their associations and the poten-
tial interactions among all three pandemics have
not been documented previously, although, as
previously mentioned, those between HIV and
cervical cancer as well as between HIV and TB
have been explored. However, there is limited
information on the impact of TB or the
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combination of TB and HIV on cervical carcino-
mas. In this study, we examined the association
between cervical cancer and a prior history of TB
by HIV serostatus in a prospective cohort of pa-
tients with cervical cancer in Botswana.
METHODS
Cervical cancer diagnosis and treatment in Bot-
swana is centralized at Princess Marina Hospital,
the largest referral hospital in the country, located
in the capital, Gaborone. Approximately 95%of all
patients diagnosed with any cancer in public
hospitals from all over the country are referred
there for confirmation of diagnosis and treatment.
In this study, we enrolled consecutive patients
referred to Princess Marina Hospital for the treat-
ment of cervical cancer between July 2013 and
January 2015. We collected demographic char-
acteristics and cancer- and TB-specific informa-
tion prospectively through patient interviews and
medical record reviews. All data were collected
before cancer treatment initiation. Prior TB dis-
ease was defined as an episode of clinically or
microbiologically diagnosedTB requiring initiation
of TB treatment at anypoint in the past. HIV testing
was performed on all patients in accordance with
Botswana’s national guidelines. Radiologic infor-
mation was unavailable in most cases, and it was
not analyzed in this study.
We first described the characteristics of patients
with cervical cancer when stratified by history of
active TB and cervical cancer. Associations were
determined using x2, t test, and Mann-Whitney
testing as appropriate. A logistical regression
model was developed to describe correlates of
prior TB disease. Variables for the model were
identified a priori on the basis of their conceptual
importance and included age at diagnosis of cer-
vical cancer, age of first sexual encounter, smok-
ing history, and presence of HIV infection. A
separate model was developed to determine the
association of CD4 cell count categories using
HIV-negative patients as referents. Odds ratios
and 95% CI were calculated. Data processing
and analyseswere performedusing Stata software
(STATA, College Station, TX).This study was ap-
proved by the institutional review boards at the
University of Pennsylvania, University of Bot-
swana, and Botswana Ministry of Health. All pa-
tients provided informed consent.
RESULTS
We enrolled 180 women during the study period,
of whom 117 (65%) were infected with HIV at the
time of their cervical cancer diagnosis. Overall, 18
(10%) patients with cervical cancer had a history
of TB disease, and 16 (89%) of them were coin-
fected with HIV. All patients with TB were treated
for their disease. All HIV-positive patients were
either already receiving antiretroviral treatment
or had started on antiretroviral treatment at the
time of cancer diagnosis. The main demographic
and clinical characteristics of the sample stratified
by history of TB infection are listed in Table 1. Our
bivariate analyses showed a significantly higher
prevalence of HIV infection among patients with
cervical cancer with a history of TB comparedwith
those without a history of TB (16 [89.8%] of 18
patients v 101 [62.3%] of 162 patients; P5 .02).
As listed in Table 2, this difference remained
significant inmultivariable analysis (adjusted odds
ratio [AOR], 21.5; 95% CI, 2.16 to 214.52; P ,
.01). Increasing age was also found to be signif-
icantly associated with prior TB disease after ac-
counting for confounders (AOR, 1.1; 95%CI, 1.01
to 1.11; P 5 .02). In a separate multivariable
model, we found that CD4 counts less than 350
cells/mL (AOR, 57.3; 95% CI, 4.44 to 740.8) and
greater than 500 cells/mm3 (AOR, 39.0; 95% CI,
3.15 to 483.89) were associated with prior TB
disease compared with no HIV infection.
DISCUSSION
In this study, we found that prior TB disease was
common in our sample of patients with cervical
cancer in Botswana. HIV infection was also highly
prevalent among patients with cervical cancer
who had TB disease before their diagnosis of
cervical cancer. Our findings are not surprising,
given the well-known association between HIV
and TB. Nevertheless, they highlight an underap-
preciated overlap of three of the most devastating
epidemics in developing countries: cervical can-
cer, HIV, and TB.
Our study design does not allow any inference
regarding the role of TB in the causal pathway of
cervical cancer, the temporal nature of events, or
thepresence of interactions betweenTB,HIV, and
cervical cancer thatmay alter the natural course of
any of those diseases. However, our results in-
dicate that thecoexistenceofpriorTBdisease,HIV
infection, and cervical cancer is common, sug-
gesting that potential interactions between two or
more of those conditions might be common as
well. Disseminated (gynecologic) TB has the po-
tential to lead todelays incervical cancerdiagnosis
and an increase in morbidity and mortality during
cancer treatment.11 Conversely, cervical cancer
diagnosis may delay the diagnosis and treatment
initiation of coexisting TB.11,12 Although TB has
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not been associated with the development of
cervical cancer, chronic TB infection and inflam-
mation in the gynecologic tract is an important
cause of infertility in the developing world.13 Thus,
the chronic inflammation due to chronic gyneco-
logic TB infectionmight be a contributing factor in
the progression toward cervical cancer.11,13,14
HIV infection is associated with a higher inci-
dence, as well as increased morbidity and mor-
tality, of both TB and cervical cancer,
independently. Whether HIV infection modifies
the relationship between TB and cervical cancer
remains to be determined.
We acknowledge the limitations of our study.
Multiple sources of bias could have confounded
our findings. Our study was performed on a con-
venience sample of all consecutive patients with
cervical cancer referred to the only cancer treat-
ment center in Botswana, and we did not have a
comparison group from the general population.
Therefore,weareunable todeterminewhether the
overall prevalence of prior TB infection was higher
than what would be expected from the general
population with or without stratifying it by HIV
status. Our inability to prospectively determine
the extent of active TB disease after cancer di-
agnosis severely limits any inference regarding the
true burden of TB in our population. Prospective
TB-attributable morbidity and mortality data are
highly needed.
Despite these limitations, we believe that these
results highlight the critical need to better under-
stand the imminent collision of three of the most
important pandemics of our time: HIV, TB, and
cancer. Although data remain scant, HIV is a
leading factor increasing the incidence of both
AIDS-defining and non–AIDS-defining cancers in
southern Africa. In Botswana, 43% of all cancers
and an even greater proportion of cancer deaths
are attributable to HIV. Future studies are needed
to determine the extent of the interactions among
these highly prevalent conditions worldwide.
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Table 1 – Characteristics of Cervical Cancer Patients by History of Prior Tuberculosis in
Botswana
Characteristic
History of Prior
Tuberculosis
(n 5 18)
No History of
Prior Tuberculosis
(n 5 162) P
Age, median (IQR) 47.3 (41.1-57.8) 47.8 (39.2-56.2) .78
Marital status, No. (%) .24
Single 13 (86.7) 90 (67.7)
Married 2 (13.3) 41 (30.8)
Divorced or widowed 0 2 (1.5)
Age of first sexual activity,
median (IQR)
18 (17-19) 18 (16-20) .39
Smoking, No. (%) 1 (5.6) 4 (2.5), .49
HIV infection, No. (%) 16 (88.9) 101 (62.3) .02
CD4 cell count, median (IQR)* 367 (261-592) 474 (343-579)
CD4 cell count, cells/mL , No. (%)* .51
, 350 6 (37.5) 22 (25.3)
351-500 3 (18.8) 26 (29.9)
. 500 7 (43.8) 39 (44.8)
Taking ART, No. (%)† 16 (100) 95 (101) .18
Viral load undetectable, No. (%) 16/16 (100) 63/66 (95.5)
Cancer type, No. (%) .53
Squamous cell carcinoma 150 (93.2) 16 (88.9)
Adenocarcinoma 11 (6.8) 2 (11.1)
Abbreviations: ART, HIV antiretroviral treatment; IQR, interquartile range.
*CD4 cell count at the time of cervical cancer diagnosis.
†Only available results presented. One case of papillary serous carcinoma excluded from the analyses.
Table 2 – Multivariate Analyses to Determine Factors Associated With Prior History of
Tuberculosis
Factor Adjusted Odds Ratio 95% CI P
Age 1.1 1.01 to 1.11 .023
HIV 21.5 2.16 to 214.52 , .01
Smoking 4.8 0.38 to 61.91 .227
CD4 cell count
HIV negative Reference Reference Reference
, 350 57.3 4.44 to 740.8 .002
351-500 14.9 0.96 to 232.78 .054
. 500 39.0 3.15 to 483.89 .004
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